Safety and Efficacy Study of ADL5859 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

This study has been completed.
Information provided by:
Cubist Pharmaceuticals Identifier:
First received: January 17, 2008
Last updated: March 5, 2015
Last verified: March 2015

The purpose of this study is to evaluate the effectiveness of ADL5859 in relieving the pain associated with diabetic peripheral neuropathy (DPN) compared with placebo and duloxetine (a marketed drug approved for the treatment of painful DPN). The pain symptoms of DPN are thought to be due to damage to nerves caused by the diabetes. The study drug, ADL5859, has not been previously tested in diabetic patients; it is anticipated to provide pain relief in DPN because it demonstrated effectiveness in animal studies.

Condition Intervention Phase
Peripheral Neuropathy
Neuropathic Pain
Drug: ADL5859
Drug: duloxetine
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2a, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Multicenter Study to Assess the Safety and Efficacy of ADL5859 100 mg BID in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

Resource links provided by NLM:

Further study details as provided by Cubist Pharmaceuticals:

Primary Outcome Measures:
  • Change from baseline in mean pain intensity score (NPRS) [ Time Frame: Week 4 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change from baseline in the mean NPRS proportion of subjects with 30% reduction in average pain score. [ Time Frame: Weekly ] [ Designated as safety issue: No ]
  • Patient Global Impression of Change (PGIC) [ Time Frame: Week 4 ] [ Designated as safety issue: No ]
  • Change in Sleep Interference Scale (SIS) from baseline [ Time Frame: Week 4 ] [ Designated as safety issue: No ]
  • Change from baseline in the evening assessment of the 24-hour overall mean pain intensity score [ Time Frame: Weekly ] [ Designated as safety issue: No ]
  • Change from baseline in NPRS at rest in the clinic [ Time Frame: Weekly ] [ Designated as safety issue: No ]
  • Change from baseline in NPRS after walking 50 feet in the clinic [ Time Frame: Weekly ] [ Designated as safety issue: No ]

Enrollment: 210
Study Start Date: November 2007
Study Completion Date: August 2008
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ADL5859
50 mg
Drug: ADL5859
2 x 50 mg capsules twice daily for 28 days
Active Comparator: Duloxetine
30 mg
Drug: duloxetine
2 x 30 mg capsules once daily for 28 days
Other Name: Cymbalta
Sham Comparator: Placebo
lactose capsules
Drug: Placebo
Two capsules filled with lactose as a non-active comparator


Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male and female subjects between 18 and 75 years of age, inclusive
  • Body weight of at least 45 kg
  • Diabetes mellitus (type I or II) that is documented to be under stable glycemic control over a period of at least 3 months, as indicated by a HbgAIC of less than or equal to 12% and a stable dose of insulin or oral diabetic medication for 90 days prior to starting study medication
  • No change in diabetic medications is planned for the duration of the study
  • Evidence of symmetrical, bilateral pain in the lower extremities due to DPN
  • Presence of daily pain due to DPN for at least 3 months
  • Score greater than or equal to 3 on the physical examination portion of the MNSI
  • Average weekly pain score of greater than or equal to 4 on the NPRS for symmetrical neuropathic pain in the feet and legs
  • For male subjects, be surgically sterile or agree to use an appropriate method of contraception
  • For female subjects of childbearing potential, be surgically sterile or using an intrauterine device, or injectable, transdermal, or combination oral contraceptive deemed highly effective by the FDA
  • Be willing and able to comply with the protocol requirements
  • Be able to understand and willing to provide written informed consent in English

Exclusion Criteria:

  • Presence of pain conditions that cannot be distinguished from DPN
  • Presence of significant renal disease, as indicated by a serum creatinine greater than or equal to 2.0 mg/dL, or presence of significant hepatic disease
  • Have a history of a seizure disorder
  • Presence of serious or unstable cardiovascular disease, respiratory disease, hematologic illness, or a psychiatric condition
  • History of evidence of symptomatic orthostatic hypotension
  • History of a major depressive disorder, generalized anxiety disorder, eating disorder, or substance abuse (including alcohol) within the past year
  • History or evidence of mania, bipolar disorder, or psychosis
  • History of allergy to acetaminophen or duloxetine
  • Score of greater than or equal to 18 on the BDI-II or score of greater than zero on item 9 of the BDI-II
  • Use of any of the following concomitant medications: fluvoxamine; quinolone antimicrobials (ciprofloxacin and enoxacin); SSRIs; SNRIs; tricyclic antidepressants; opioids; NSAIDS; anticonvulsants; aspirin (with the exception of low-dose aspirin as cardiovascular prophylaxis); or CYP3A and P-glycoprotein transporter inhibitors
  • Pregnant, lactating, or plans to become pregnant during the study
  • Presence of foot or toe amputation
  • Participation in another study with an investigational compound within the previous 30 days prior to study medication administration, or concurrent participation in another clinical study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00603265

  Show 27 Study Locations
Sponsors and Collaborators
Cubist Pharmaceuticals
Study Director: Bruce Berger, MD Cubist Pharmaceuticals
  More Information

Additional Information:
No publications provided

Responsible Party: Bruce Berger, MD, Adolor Corporation Identifier: NCT00603265     History of Changes
Other Study ID Numbers: 33CL231
Study First Received: January 17, 2008
Last Updated: March 5, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by Cubist Pharmaceuticals:
Diabetic Peripheral Neuropathy
Neuropathic Pain

Additional relevant MeSH terms:
Diabetic Neuropathies
Peripheral Nervous System Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Nervous System Diseases
Neurologic Manifestations
Neuromuscular Diseases
Signs and Symptoms
Adrenergic Agents
Adrenergic Uptake Inhibitors
Antidepressive Agents
Central Nervous System Agents
Dopamine Agents
Dopamine Uptake Inhibitors
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Sensory System Agents
Serotonin Agents
Serotonin Uptake Inhibitors
Therapeutic Uses processed this record on June 28, 2015